Evidence map›Paper›PMID 21917605›Full record

ArticleJournal of the National Cancer Institute2011

Molecular characterization of the tumor-suppressive function of nischarin in breast cancer.

Somesh Baranwal, Yanfang Wang, Rajamani Rathinam, Jason Lee, Lianjin Jin, Robin McGoey, Yuliya Pylayeva, Filippo Giancotti, Gerard C Blobe, Suresh K Alahari

Open access · hybridAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Somesh BaranwalDepartment of Biochemistry and Molecular Biology, Stanley S. Scott Cancer Center, Louisiana State University School Of Medicine, 1901 Perdido St, New Orleans, LA 70112, USA.
Yanfang Wang
Rajamani Rathinam
Jason Lee
Lianjin Jin
Robin McGoey
Yuliya Pylayeva
Filippo Giancotti
Gerard C Blobe
Suresh K Alahari
University Medical Center New Orleans · USLouisiana State University Health Sciences Center New Orleans · USDuke University · US

Funding

A Novel Regulator of Cancer Cell Migration and InvasionR01CA115706 · NCI · LSU HEALTH SCIENCES CENTER · PI ALAHARI, SURESH K. · 2006 to 2010
$1.0M
NCI NIH HHS 5R01CA115706NCRR NIH HHS P20RR078766
6 · The paper itself

Abstract

backgroundNischarin (encoded by NISCH), an α5 integrin-binding protein, has been identified as a regulator of breast cancer cell invasion. We hypothesized that it might be a tumor suppressor and were interested in its regulation.

methodsWe examined nischarin expression in approximately 300 human breast cancer and normal tissues using quantitative polymerase chain reaction and immunohistochemistry. Loss of heterozygosity analysis was performed by examining three microsatellite markers located near the NISCH locus in normal and tumor tissues. We generated derivatives of MDA-MB-231 human metastatic breast cancer cells that overexpressed nischarin and measured tumor growth from these cells as xenografts in mice; metastasis by these cells after tail vein injection; and α5 integrin expression, Rac, and focal adhesion kinase (FAK) signaling using western blotting. We also generated clones of MCF-7 human breast cancer cells in which nischarin expression was silenced and measured tumor growth in mouse xenograft models (n = 5 for all mouse experiments). P values were from two-sided Student t tests in pairwise comparisons.

resultsNormal human breast tissue samples had statistically significantly higher expression of nischarin mRNA compared with tumor tissue samples (mean level in normal breast = 50.7 [arbitrary units], in breast tumor = 16.49 [arbitrary units], difference = 34.21, 95% confidence interval [CI] = 11.63 to 56.79, P = .003), and loss of heterozygosity was associated with loss of nischarin expression. MDA-MB-231 cells in which nischarin was overexpressed had statistically significantly reduced tumor growth and metastasis compared with parental MDA-MB-231 cells (mean volume at day 40, control vs nischarin-expressing tumors, 1977 vs 42.27 mm(3), difference = 1935 mm(3), 95% CI = 395 to 3475 mm(3), P = .025). Moreover, MCF-7 tumor xenografts in which nischarin expression was silenced grew statistically significantly faster than parental cells (mean volume at day 63, tumors with scrambled short hairpin RNA [shRNA] vs with nischarin shRNA, 224 vs 1262 mm(3), difference = 1038 mm(3), 95% CI = 899.6 to 1176 mm(3), P < .001). Overexpression of nischarin was associated with decreased α5 integrin expression, FAK phosphorylation, and Rac activation.

conclusionNischarin may be a novel tumor suppressor that limits breast cancer progression by regulating α5 integrin expression and subsequently α5 integrin-, FAK-, and Rac-mediated signaling.

Indexed as

AnimalsBlotting, WesternBreast NeoplasmsCarcinoma, Ductal, BreastCell Line, TumorDisease ProgressionEnzyme ActivationFemaleFocal Adhesion Kinase 1Gene Expression Regulation, NeoplasticGene SilencingHumansImidazoline ReceptorsImmunohistochemistryIntegrin alpha5Intracellular Signaling Peptides and ProteinsFocal Adhesion Kinase 1Imidazoline ReceptorsIntegrin alpha5Intracellular Signaling Peptides and ProteinsLIMK1 protein, humanLim KinasesNISCH protein, humanp21-Activated KinasesPTK2 protein, humanrac GTP-Binding ProteinsRNA, Messenger

Identifiers

PMID21917605
PMCPMC3196482
OpenAlexW2138213364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.